Details

Autor(en) / Beteiligte

• Ling, Alexander L.
• Solomon, Isaac H.
• Landivar, Ana Montalvo
• Nakashima, Hiroshi
• Woods, Jared K.
• Santos, Andres
• Masud, Nafisa
• Fell, Geoffrey
• Mo, Xiaokui
• Yilmaz, Ayse S.
• Grant, James
• Zhang, Abigail
• Bernstock, Joshua D.
• Torio, Erickson
• Ito, Hirotaka
• Liu, Junfeng
• Shono, Naoyuki
• Nowicki, Michal O.
• Triggs, Daniel
• Halloran, Patrick
• Piranlioglu, Raziye
• Soni, Himanshu
• Stopa, Brittany
• Bi, Wenya Linda
• Peruzzi, Pierpaolo
• Chen, Ethan
• Malinowski, Seth W.
• Prabhu, Michael C.
• Zeng, Yu
• Carlisle, Anne
• Rodig, Scott J.
• Wen, Patrick Y.
• Lee, Eudocia Quant
• Nayak, Lakshmi
• Chukwueke, Ugonma
• Gonzalez Castro, L. Nicolas
• Dumont, Sydney D.
• Batchelor, Tracy
• Kittelberger, Kara
• Tikhonova, Ekaterina
• Miheecheva, Natalia
• Tabakov, Dmitry
• Shin, Nara
• Gorbacheva, Alisa
• Shumskiy, Artemy
• Frenkel, Felix
• Aguilar-Cordova, Estuardo
• Aguilar, Laura K.
• Krisky, David
• Wechuck, James
• Manzanera, Andrea
• Matheny, Chris
• Tak, Paul P.
• Barone, Francesca
• Kovarsky, Daniel
• Tirosh, Itay
• Suvà, Mario L.
• Wucherpfennig, Kai W.
• Ligon, Keith
• Reardon, David A.
• Chiocca, E. Antonio

Titel

Clinical trial links oncolytic immunoactivation to survival in glioblastoma

Ist Teil von

• Nature (London), 2023-11, Vol.623 (7985), p.157-166

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Immunotherapy failures can result from the highly suppressive tumour microenvironment that characterizes aggressive forms of cancer such as recurrent glioblastoma (rGBM) 1 , 2 . Here we report the results of a first-in-human phase I trial in 41 patients with rGBM who were injected with CAN-3110—an oncolytic herpes virus (oHSV) 3 . In contrast to other clinical oHSVs, CAN-3110 retains the viral neurovirulence ICP34.5  gene transcribed by a nestin promoter; nestin is overexpressed in GBM and other invasive tumours, but not in the adult brain or healthy differentiated tissue 4 . These modifications confer CAN-3110 with preferential tumour replication. No dose-limiting toxicities were encountered. Positive HSV1 serology was significantly associated with both improved survival and clearance of CAN-3110 from injected tumours. Survival after treatment, particularly in individuals seropositive for HSV1, was significantly associated with (1) changes in tumour/PBMC T cell counts and clonal diversity, (2) peripheral expansion/contraction of specific T cell clonotypes; and (3) tumour transcriptomic signatures of immune activation. These results provide human validation that intralesional oHSV treatment enhances anticancer immune responses even in immunosuppressive tumour microenvironments, particularly in individuals with cognate serology to the injected virus. This provides a biological rationale for use of this oncolytic modality in cancers that are otherwise unresponsive to immunotherapy (ClinicalTrials.gov: NCT03152318 ). Treatment with the oncolytic herpes virus CAN-3110 is associated with improved survival responses in patients with recurrent glioblastoma, particularly in individuals who are seropositive for HSV1.